Nova Sample Clauses

Nova. (print) Title: Member -------------------------------- Address: c/o Highland Capital Partners Two International Place Boston, MA 02110 Fax: (617) 531-1550 HIGHLAND ENTREPRENEURS' FUND III LIMITED PARTNERSHIP By: HEF III, LLC, its General Partner By: /s/ Daniel J. Nova -----------------------------------
Nova. (print) Title: Member --------------------------------------- Address: c/o Highland Capital Partners Two International Place Boston, MA 02110 Fax: (617) 531-1550 SIGNATURE PAGE TO eTOYS INC. AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT INVESTORS: idealab! CAPITAL PARTNERS I-A, LP By its General Partner, idealab! Capital Management I, LLC By: /s/ William Elkus ---------------------------------------- William Elkus Managing Member Address: c/o idealab! Capital Partners 130 West Union Street Pasadena, CA 91103 Fax: (626) 535-2881 idealab! CAPITAL PARTNERS I-B, LP By its General Partner, idealab! Capital Management I, LLC By: /s/ William Elkus ---------------------------------------- William Elkus Managing Member Address: c/o idealab! Capital Partners 130 West Union Street Pasadena, CA 91103 Fax: (626) 535-2881 SIGNATURE PAGE TO eTOYS INC. AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT INVESTORS: BESSEMER VENTURE PARTNERS IV L.P. By: Deer IV & Co. LLC, General Partner By: /s/ Robert H. Buescher ------------------------------------------ Name: Robert H. Buescher Title: Manager Address: 1400 Old Country Road, Suite 407 Westbury, NY 11590 Fax: (516) 997-2371 BESSEMER VENTURE INVESTORS L.P. By: Deer IV & Co. LLC, General Partner By: /s/ Robert H. Buescher ------------------------------------------ Name: Robert H. Buescher Title: Manager Address: 1400 Old Country Road, Suite 407 Westbury, NY 11590 Fax: (516) 997-2371 BESSEC VENTURES IV L.P. By: Deer IV & Co. LLC, General Partner By: /s/ Robert H. Buescher ------------------------------------------ Name: Robert H. Buescher Title: Manager Address: 1400 Old Country Road, Suite 407 Westbury, NY 11590 Fax: (516) 997-2371 SIGNATURE PAGE TO eTOYS INC. AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT INVESTORS: SEQUOIA CAPITAL VIII SEQUOIA INTERNATIONAL TECHNOLOGY PARTNERS SEQUOIA INTERNATIONAL TECHNOLOGY PARTNERS Q CMS SEQUOIA 1997 By: /s/ Michael Moritz ------------------------------------------ Name: Michael Moritz ---------------------------------------- (print) Title: --------------------------------------- Address: 3000 Sand Hill Road Building 4, Suite 280 Menlo Park, CA 94025 Fax: (650) 854-2977 SIGNATURE PAGE TO eTOYS INC. AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT INVESTORS: VLG INVESTMENTS 1998 By: /s/ Illegible ------------------------------------------ Name: ---------------------------------------- (print) Title: --------------------------------------- Address: c/o Venture Law Group 2800 Sand Hill R...
Nova. Factor represents that it has the authority to enter into this Agreement and that its execution of this Agreement and its performance of its obligations hereunder will not conflict with and is not prohibited by any other agreement to which Nova Factor is a party.
Nova. Factor shall not make any performance claims or engage in any promotional activities with respect to Product except for the distribution of Product literature prepared by Biogen and any other activities expressly approved by Biogen.
Nova. Factor represents and warrants that it is currently eligible to participate as a provider in the Medicaid program in each state in the Territory except those states listed on Schedule "J", attached hereto and incorporated herein by reference, and covenants that it will maintain such eligibility during the term of this Agreement. Nova Factor may amend Schedule "J" in its sole discretion to add additional states and shall provide Centocor with prompt notice of any such amendment, provided that Nova Factor shall not add any state to Schedule "J" unless that state has changed its laws to require an in-state pharmacy presence for eligibility in its Medicaid program. Nova Factor shall remove a state from Schedule "J" (and shall provide notice to Centocor of such removal) when the state no longer requires an in-state pharmacy presence for the eligibility in the state's Medicaid program.
Nova. Factor shall use its best efforts to resolve reimbursement issues of customers who would like to purchase Product from Nova Factor. If Biogen has engaged
Nova. Factor represents that it now has and shall maintain a full force during the term of this Agreement all federal and state pharmacy, wholesaler and other licenses or approvals required by Nova Factor to fulfill its obligations under this Agreement, except as otherwise set forth in Section 12.3, and except that Nova Factor shall not be required to maintain its licenses in any state which amends its laws and regulations to require an in-state pharmacy presence as a requirement for licensing if the new requirement would materially increase the costs incurred by Nova Factor in performing its obligations under this Agreement. Nova Factor shall provide Biogen with notice of any communications with Pharmacy licensing boards which relate to potential problems with facilities, operations or procedures used by Nova Factor in its distribution of Product, including notices of inquiries, investigations or inspections and resulting findings.
Nova. (print) Title: Member -------------------------------- Address: c/o Highland Capital Partners Two International Place Boston, MA 02110 Fax: (617) 531-1550 SIGNATURE PAGE TO eTOYS INC. SECOND AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT INVESTORS: HIGHLAND CAPITAL PARTNERS IV LIMITED PARTNERSHIP By: /s/ Daniel J. Nova -----------------------------------
Nova. Factor shall notify the designated contact in Biogen's Drug Safety and Medical Information Group (or such other person as Biogen may designate), by telephone, immediately (but in no event later than one (1) business day) after receipt of notice of an Adverse Event associated with the Product or after Nova Factor or any of its agents or employees becomes aware of an Adverse Event associated with the Product. Nova Factor shall confirm each notice of an Adverse Event by providing to Biogen within two (2) business days a written report in the format required for Adverse Events by the FDA, or, at Biogen's request, in the format provided by Biogen. All communications and reports regarding Adverse Events shall be sent to: Biogen, Inc., 14 Cambridge Center, Cambridge, MA 02142, Attention: Director - Drug Safety and Medical Information Group, Fax No. (617) 679-2342, or to such other address as Biogen may from time to time designate.